Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality

Future Oncol. 2010 Jun;6(6):877-80. doi: 10.2217/fon.10.65.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Antineoplastic Agents, Hormonal / pharmacokinetics
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biotransformation / drug effects
  • Breast Neoplasms / complications
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Citalopram / adverse effects
  • Citalopram / pharmacology
  • Citalopram / therapeutic use
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP2D6 / metabolism
  • Cytochrome P-450 CYP2D6 Inhibitors*
  • Denmark / epidemiology
  • Depression / complications
  • Depression / drug therapy
  • Drug Interactions
  • Estrogens*
  • Female
  • Humans
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / mortality
  • Prognosis
  • Recurrence
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Tamoxifen / analogs & derivatives
  • Tamoxifen / blood
  • Tamoxifen / pharmacokinetics
  • Tamoxifen / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Estrogens
  • Serotonin Uptake Inhibitors
  • Tamoxifen
  • Citalopram
  • 4-hydroxy-N-desmethyltamoxifen
  • Cytochrome P-450 CYP2D6